Painreform Ltd (PRFX) Stock Price, Quote & News

Company Profile

PainReform Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair operatio...

Industry: Drug Manufacturers - Specialty & Generic

Sector: Healthcare

Phone: 972 3 7177050

Website: www.painreform.com

Address:

65 Yigal Alon St., Tel Aviv, Israel

StockStratigizer Jul. 28 at 5:19 PM

$PRFX Catalysts brewing

1 · Reply

Weimanator Jul. 28 at 1:55 PM

$PRFX today could be the day. Stay alert!! 🚨 ‼️ 🔔

0 · Reply

KhalidsCapital Jul. 25 at 4:23 PM

TGL news news news! This is the type of sleeper play that turns $0.90 into $5 when no one’s paying attention. AI + blockchain platform goes live this quarter 2.7M users already And barely a soul is watching... That’s my favorite setup. $XWEL $PRFX $PEV $OPGN

0 · Reply

Weimanator Jul. 25 at 3:40 PM

$PRFX let’s go! Love being an investor with this sleeping GIANT :)

0 · Reply

Mkm950 Jul. 24 at 7:30 PM

$PRFX

0 · Reply

RayIngersoll776 Jul. 23 at 4:25 PM

$PRFX fights post-surgical pain; AITX fights security inefficiency—with robotic units and financial backing that aligns with shareholder value.

0 · Reply

TheRealShortSqueezy Jul. 23 at 2:33 PM

$PRFX In before the crowd. Watch them chase. Avg: 1.50$ Waiting on catalyst press release.

0 · Reply

YouVSYou Jul. 23 at 12:39 PM

$RR catalyst tomorrow $2.24/2.31/2.39 Bull pennant breakout $IBG $ONCO $PRFX $GPRO

0 · Reply

YouVSYou Jul. 22 at 12:59 PM

$IXHL $OPEN $PRFX

2 · Reply

Weimanator Jul. 21 at 3:52 PM

$PRFX any day this is going to pop. Stay on your feet!

0 · Reply

PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio

May 27, 2025, 12:12 PM EDT - 2 months ago

Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

May 7, 2025, 4:30 PM EDT - 2 months ago

PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

Apr 10, 2025, 8:30 AM EDT - 3 months ago

PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

Apr 7, 2025, 5:00 PM EDT - 4 months ago

PainReform Provides Year-End Business Update

Mar 5, 2025, 11:00 AM EST - 5 months ago

PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

Feb 18, 2025, 8:30 AM EST - 5 months ago

PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

Dec 27, 2024, 8:30 AM EST - 7 months ago

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

Nov 20, 2024, 8:30 AM EST - 8 months ago

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

Nov 7, 2024, 5:00 PM EST - 9 months ago

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Sep 11, 2024, 8:30 AM EDT - 11 months ago

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

Sep 10, 2024, 9:46 AM EDT - 11 months ago

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

Aug 20, 2024, 8:30 AM EDT - 1 year ago

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

Aug 7, 2024, 10:00 AM EDT - 1 year ago

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

Aug 1, 2024, 8:30 AM EDT - 1 year ago

PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

May 31, 2024, 4:15 PM EDT - 1 year ago

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

May 15, 2024, 4:05 PM EDT - 1 year ago

PainReform Provides Business Update for the First Quarter of 2024

May 8, 2024, 8:30 AM EDT - 1 year ago

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

Apr 18, 2024, 2:19 PM EDT - 1 year ago

PainReform Announces Closing of $4 Million Public Offering

Apr 9, 2024, 9:00 AM EDT - 1 year ago

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

Apr 2, 2024, 8:30 AM EDT - 1 year ago

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Jan 22, 2024, 8:30 AM EST - 1 year ago

PainReform to Present at the Microcap Conference in Atlantic City

Jan 3, 2024, 8:30 AM EST - 1 year ago

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

Dec 26, 2023, 6:00 PM EST - 1 year ago

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

Nov 15, 2023, 4:05 PM EST - 1 year ago

PainReform Provides Business Update for the Third Quarter of 2023

Sep 11, 2023, 8:30 AM EDT - 2 years ago

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

Sep 7, 2023, 10:00 AM EDT - 2 years ago

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

Sep 5, 2023, 8:30 AM EDT - 2 years ago

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

Aug 10, 2023, 4:05 PM EDT - 2 years ago

PainReform Provides Business Update for the Second Quarter of 2023

Jul 19, 2023, 9:00 AM EDT - 2 years ago

PainReform Regains Compliance with Nasdaq Continued Listing Requirements

Jul 14, 2023, 2:35 PM EDT - 2 years ago

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

Jul 12, 2023, 9:05 AM EDT - 2 years ago

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

Jun 15, 2023, 8:30 AM EDT - 2 years ago

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

Jun 7, 2023, 4:30 PM EDT - 2 years ago

PainReform Provides Regulatory Update on Second Part of its Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

May 15, 2023, 4:45 PM EDT - 2 years ago

PainReform Provides Business Update for the First Quarter of 2023

May 1, 2023, 8:30 AM EDT - 2 years ago

PainReform Announces Positive Safety Data in First Part of Phase 3 Clinical Trial of PRF-110 in Patients Undergoing Bunionectomy Surgery

Mar 28, 2023, 9:10 AM EDT - 2 years ago

PainReform Completes First Part of Phase 3 Clinical Trial in Patients Undergoing Bunionectomy Surgery

Mar 16, 2023, 8:00 AM EDT - 2 years ago

PainReform Provides Year-End Business Update; Commences Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Feb 7, 2023, 4:05 PM EST - 2 years ago

PainReform Ltd. (NASDAQ: PRFX) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement

Nov 15, 2022, 8:30 AM EST - 2 years ago

PainReform Provides Business Update for the Third Quarter of 2022

Sep 1, 2022, 8:00 AM EDT - 3 years ago

PainReform to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Aug 16, 2022, 8:05 AM EDT - 3 years ago

PainReform Provides Business Update for the Second Quarter of 2022

Apr 12, 2022, 9:00 AM EDT - 3 years ago

PainReform to Present at The Noble Capital Markets' Eighteenth Annual Investor Conference on April 20th

Mar 21, 2022, 9:25 AM EDT - 3 years ago

PainReform to Present at the 2022 Virtual Growth Conference Presented by Maxim Group LLC and hosted by M-Vest on March 28th - 30th

Mar 17, 2022, 8:00 AM EDT - 3 years ago

PainReform Provides Year-End Business Update; on Track to Commence Phase 3 Trial of PRF-110 for Non-Opiate Post-Operative Pain Relief in the Second Half of 2022

Dec 14, 2021, 8:30 AM EST - 3 years ago

PainReform CEO to Participate in the Benzinga All Access Event on December 16th

Nov 16, 2021, 8:00 AM EST - 4 years ago

PainReform Provides Business Update for the Third Quarter of 2021

Oct 14, 2021, 8:30 AM EDT - 4 years ago

PainReform to Present at Dawson James Securities 6th Annual Small Cap Growth Conference on October 21, 2021

Aug 16, 2021, 8:00 AM EDT - 4 years ago

PainReform Provides Business Update for the Second Quarter of 2021

May 13, 2021, 8:15 AM EDT - 4 years ago

PainReform Provides Business Update for the First Quarter of 2021

StockStratigizer Jul. 28 at 5:19 PM

$PRFX Catalysts brewing

1 · Reply

Weimanator Jul. 28 at 1:55 PM

$PRFX today could be the day. Stay alert!! 🚨 ‼️ 🔔

0 · Reply

KhalidsCapital Jul. 25 at 4:23 PM

0 · Reply

Weimanator Jul. 25 at 3:40 PM

$PRFX let’s go! Love being an investor with this sleeping GIANT :)

0 · Reply

Mkm950 Jul. 24 at 7:30 PM

$PRFX

0 · Reply

RayIngersoll776 Jul. 23 at 4:25 PM

$PRFX fights post-surgical pain; AITX fights security inefficiency—with robotic units and financial backing that aligns with shareholder value.

0 · Reply

TheRealShortSqueezy Jul. 23 at 2:33 PM

$PRFX In before the crowd. Watch them chase. Avg: 1.50$ Waiting on catalyst press release.

0 · Reply

YouVSYou Jul. 23 at 12:39 PM

$RR catalyst tomorrow $2.24/2.31/2.39 Bull pennant breakout $IBG $ONCO $PRFX $GPRO

0 · Reply

YouVSYou Jul. 22 at 12:59 PM

$IXHL $OPEN $PRFX

2 · Reply

Weimanator Jul. 21 at 3:52 PM

$PRFX any day this is going to pop. Stay on your feet!

0 · Reply

YouVSYou Jul. 20 at 5:11 PM

$PRFX HODL

0 · Reply

BigTimePennyStocks Jul. 20 at 4:32 PM

Small-Caps with Catalysts this week: 👇 ( $ORKT, $ASTI, $PRFX, $RSLS, $LUCY, etc...) #NASDAQ #NYSE

0 · Reply

Weimanator Jul. 16 at 4:05 PM

$PRFX noobies will be shooketh when they see how many shekels this will goeth in a small time frame. PRFX will buildeth patience in you.

0 · Reply

STOCKSGambino Jul. 16 at 3:44 PM

$PRFX https://x.com/StocksGambino/status/1945508897051324513

0 · Reply

YouVSYou Jul. 16 at 3:12 PM

$PRFX $$NICE upside candidate

0 · Reply

STOCKSGambino Jul. 16 at 3:09 PM

$PRFX took for swing low float nanocap bio with upcoming cat - 65k borrows - has 1.86m float & 1.89m OS with 10m AS cap - last offer @ $3.83 catalyst; - Expected closing of the transaction by the end of July 2025. PainReform Ltd. has entered into a Preferred Stock Purchase Agreement to acquire 51% of LayerBio's share capital. The transaction is expected to close by the end of July 2025.

0 · Reply

Weimanator Jul. 16 at 2:01 PM

$PRFX we’ll get moving soon, sit back and relax in here because nothing will happen until it happens 🤣 IYKYK

0 · Reply

max315 Jul. 15 at 4:04 PM

$PRFX someone trying to make this move

1 · Reply

Turkish_Warren_Buffett Jul. 15 at 1:02 PM

$PRFX this shit moves as snail...no moves..

1 · Reply

Turkish_Warren_Buffett Jul. 11 at 10:58 AM

$PRFX Bye bye great scam company ! Go OTC

1 · Reply

Turkish_Warren_Buffett Jul. 11 at 10:08 AM

$PRFX short it down...it will go back under 1

0 · Reply

jParkz Jul. 10 at 11:00 PM

News PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio https://marketwirenews.com/news-releases/painreform-ltd-enters-into-a-strategic-investment-ag-7625879234532189.html $PRFX

0 · Reply

Market Cap	3.00M
Revenue (ttm)	0.00
Net Income (ttm)	-14.59M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	108,023
Avg Vol	185,102
Day's Range	N/A - N/A
Shares Out	2.01M
Stochastic %K	46%
Beta	0.56
Analysts	Strong Buy
Price Target	$47.99